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We report an English kindred affected across 4 generations with a hereditary neuropathy associated with
debilitating neuropathic pain as the main clinical feature. The principal ﬁnding on clinical examination
was sensory loss, and there was variable motor dysfunction. Electrophysiological studies revealed mild
features of demyelination with median conduction velocity in the intermediate range. There was an auto-
somal-dominant pattern of inheritance, and genetic testing revealed a novel heterozygous Trp101X
mutation in exon 3 coding for a portion of the extracellular domain of myelin protein zero. This is pre-
dicted to lead to premature termination of translation. Myelin protein zero is a key structural component
of compact myelin, and over 100 mutations in this protein have been reported, which can give rise to
neuropathies with either axonal, demyelinating, or intermediate features encompassing a wide range
of severity. Chronic pain is an increasingly recognised sequela of certain hereditary neuropathies and
may be musculoskeletal or neuropathic in origin. In this kindred, the neuropathy was relatively mild
in severity, however, neuropathic pain was an important and disabling outcome.
 2012 International Association for the Study of Pain. Published by Elsevier B.V.
Open access under CC BY license.1. Introduction We describe a multigenerational English kindred in whom the pre-Certain hereditary neuropathies have a strong association with
neuropathic pain. Classically, such neuropathies demonstrate sen-
sory involvement and, particularly, injury to dorsal root ganglion
neurons with unmyelinated axons. Examples include Fabry disease
[36], familial amyloid neuropathy [22], and hereditary neuropa-
thies due to mutations in serine palmitoyltransferase, long-chain
base subunit-1 (SPTLC-1) [4,11], or RAB7 [12,33]. Some forms of
Charcot-Marie-Tooth disease (CMT) are due to mutations in myelin
proteins and can manifest prominent sensory involvement, for in-
stance, CMT4F, which is caused by mutations in the periaxin gene
[10,31]. The mechanisms underlying neuropathic pain generation
are less clear in the context of demyelinating neuropathies. Myelin
protein zero (MPZ) is the major glycoprotein of peripheral nerve
myelin, and homotypic interactions between the extracellular do-
mains of MPZ are required for the compaction of myelin lamellae.
A large number of different MPZ mutations have been reported in
association with CMT and can include axonal, demyelinating, or
intermediate forms of CMT, with differing levels of severity [29].Study of Pain. Published by Elsevie
storation, Wolfson Centre for
ondon, London SE1 1UL, UK.
nnett).senting feature was neuropathic pain with mild or absent motor
dysfunction. This was found to be due to an intermediate form of
CMT as a consequence of a novel mutation in the MPZ gene.
2. Methods
2.1. Patients and clinical evaluation
All the patients were seen by D.L.H.B. and P.R.J.B. at the Neurol-
ogy Department, King’s College Hospital; 2 patients consented to
detailed quantitative sensory testing as part of the Pain in Neurop-
athy Study (National Research Ethics Service Ref. 10/H07056/35).
Genetic testing was performed following informed consent, and
sequencing of the MPZ gene was undertaken at the National Genet-
ics Reference Laboratory, Manchester, UK. Nucleotide numbering is
given according to the MPZ cDNA sequence with Genebank acces-
sion number D10537. Nerve conduction studies were performed
using standard techniques. The Charcot-Marie-Tooth Disease Neu-
ropathy Score (CMTNS), a validated scale for assessing impairment
in CMT, was calculated as per Shy et al. [28]. This is a composite
measurement that involves sensory and motor symptoms and
examination ﬁndings, as well as electrophysiological parameters.
A score of 10 or less indicates a mild neuropathy; between 11
and 20, the neuropathy is considered moderate; and over 21 isr B.V. Open access under CC BY license.
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Fig. 1. Family pedigree. Roman numerals represent the 1st to the 4th generation.
Square, man; Circle, woman; Shaded symbol represents affected patients; Arrow
points to the index case. Numbered subjects were seen by their health care team
and are described in this report. Patients 5 and 2 were consented and entered the
Pain in Neuropathy Study in which quantitative sensory testing was performed.
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Medical Research Council motor sum score, power was graded as
per the Medical Research Council power scale (0-5) in the follow-
ing muscle groups: arm abduction at the shoulder, elbow ﬂexion,
wrist extension, abduction of the index ﬁnger, hip ﬂexion, knee
extension, and ankle dorsiﬂexion, so that the maximum score is 70.
2.2. Quantitative sensory testing
Quantitative sensory testing following informed consent was
performed in the S1 dermatome territory bilaterally according to
the German DFNS protocol [24]. This protocol includes 13 param-
eters measuring temperature detection and pain thresholds,
mechanical detection and pain thresholds, mechanical pain sensi-
tivity, signs of allodynia, and wind-up ratio among others, allowing
characterisation of sensory proﬁles. The ﬁndings in the 2 evaluated
patients were compared with a control Caucasian population from
Germany by means of z scores in which the z score represents the
result of a raw score minus the mean of the population, and this is
further divided by the SD of the population [24]. Z-scores above or
below ±1.96 SDs would represent hyper- or hyposensitivity and
hyper- or hypoalgesia, depending on the evaluated parameter.
2.3. Skin biopsy for intraepidermal nerve ﬁbre density (IENFD) analysis
Following informed consent, a 3-mm punch skin biopsy was
taken from the lower leg, 10 cm above the lateral malleolus, in
patients and normal controls after anaesthetic injection of 1%
lidocaine. Skin samples were ﬁxed using 2% periodate-lysine-
paraformaldehyde and then preserved in sucrose before being
blocked and further processed into 50-lm sections. Samples were
randomly selected for staining using goat antitype IV collagen
antibody (1:400; Millipore, Temecula, CA, USA) followed by Alexa
488 donkey antigoat (1:1000; Alexa Fluor, Invitrogen, Life Tech-
nologies, Grand Island, NY, USA) to mark the basal membrane,
nerve ﬁbres were stained using rabbit anti-PGP (protein gene
product) 9.5 Ab (1:2000; Ultraclone Ltd, Yarmouth, Isle of Wight,
UK) and Cy3 antirabbit (1:500; Jackson Immunoresearch, West
Grove, PA, USA). Further analysis of myelinated structures in
the skin was performed according to published literature [23]
using rat antimyelin basic protein Ab (1:200; AbCam, Cambridge,
MA, USA) and Alexa 488 anti-rat (1:1000; Alexa Fluor, Invitro-
gen). Images were taken using a Zeiss LSM 710 upright confocal
microscope, with a Plan-Apochromat objective at 20 magniﬁca-
tion (Carl Zeiss MicroImaging GmbH, Jena, Germany). Eighteen 2-
lm-interval images were acquired each time and the maximum
intensity projection tool was used. Control samples and the pa-
tient’s sample were analyzed by the same investigator (J.D.R.).
Analysis was performed as per published guidelines [13]. PGP
9.5-positive nerve ﬁbres crossing the basal membrane were
counted and a measurement of the length of the sample was then
obtained. IENFD counts are given in number of ﬁbres per millime-
tre length of epidermis.
3. Results
3.1. Clinical features
Six patients belonging to an English kindred over 4 generations
(Fig. 1) were reviewed at the Neuromuscular Clinic, King’s College
Hospital. In all cases, the presenting complaint was with sensory
symptoms. All of the patients described pain that was localised
to the toes, heels, and ankles, with a mean intensity on the numer-
ical rating score of 7 of 10. The pain was described as being local-
ised within deep structures of the ankle and foot. Descriptors
included burning, aching, shooting, and throbbing pain. Pain wasexacerbated by cold in 3 of the family members. Five of the 6 pa-
tients required medication for the management of their pain
(including tricyclic antidepressants, gabapentinoids, opiates, and
topical treatment with 5% lidocaine plaster), which were partially
effective. Other sensory manifestations included numbness of the
feet and intermittent paraesthesia. Only one patient complained
of symptoms in the upper limbs, which consisted of intermittent
paraesthesia. Motor symptoms were rare, however, one patient
complained of weakness around the ankles.
On clinical examination (Table 1), ﬁndings in the cranial nerves
were normal, including pupillary reactions. One patient had pes ca-
vus. Power was normal in all the subjects except for a mild reduc-
tion in strength of ankle dorsiﬂexion in one subject. Sensory
examination demonstrated in the majority of cases a distal, sym-
metrical sensory loss. None of the patients had touch-evoked allo-
dynia. In most cases, ankle jerks were absent, but otherwise, deep
tendon reﬂexes were preserved.
3.1.1. Neurophysiology
Nerve conduction studies were performed in 4 of the affected
subjects. The ﬁndings are summarised in Table 2 and demon-
strated mild conduction slowing; the median nerve motor conduc-
tion velocity varied between 38 and 43 m/s, and f-waves were
prolonged. The amplitudes of compound motor and sensory nerve
action potentials were well maintained.
3.1.2. Genetic analysis
In relation to genetic testing of the proband (Patient 5), molec-
ular analysis of the PMP22 gene did not show duplication or dele-
tion, and sequencing of the GJB1 gene did not reveal any
mutations. Sequencing of the MPZ gene revealed a heterozygous
G-to-A substitution at nucleotide 302 within exon 3. This is pre-
dicted to result in a premature termination of translation at codon
101. This codon normally encodes tryptophan, which is located in
the extracellular domain of the protein [27]; the mutation would
be predicted to result in a truncated protein lacking the transmem-
brane domain. All affected family members who were assessed
were found to have this mutation.
3.2. CMTNS, quantitative sensory testing, IENFD measurements
The CMTNS was calculated in 4 patients and the score ranged
between 6 and 9 (Table 1), which is indicative of a mild neuropathy
[28].
Quantitative sensory testing following the DFNS protocol was
performed in 2 of the subjects. Findings can be seen in Fig. 2. Z-
scores are compared against gender- and age-matched controls.
Testing was performed bilaterally in the S1 dermatome, which
was symptomatic in both patients, and generally, ﬁndings were
Table 1
Clinical features of the reported kindred.
Examination
Age of onset Age at
assessment, y
Pain Pes
cavus
MRC sum score
(max 70)
Pin prick Light touch Joint position
sense
Vibration
sense
CMTNS
Patient 1 1st decade 18 Yes No 70 Normal Normal Normal Normal ⁄
Patient 2 1st decade 23 Yes No 68 Normal Normal Normal Normal 7
Patient 3 2nd decade 25 Yes No 70 Lost to the ankles Normal Normal Lost to the toes 8
Patient 4 3rd decade 40 Yes No 70 Lost to wrists and knees Normal Normal Lost to the toes 9
Patient 5 3rd decade 42 Yes No 70 Lost to the ankles Normal Normal Normal 6
Patient 6 4th decade 44 Yes Yes 70 Lost to the ankles Lost to the toes Lost to the toes Lost to the toes ⁄
MRC sum score, summation of the Medical Research Council (MRC) grades from 0 to 5 in bilaterally tested muscles (max. score of 70); CMTNS, Charcot-Marie-Tooth disease
Neuropathy Score, which has a maximum score of 36.
Age of pain onset ranged from the 1st to the 4th decade. All the patients reported pain as their presenting complaint.
Table 2
Nerve conduction studies done as part of the clinical assessment.
Sensory studies Motor studies
R Median R Ulnar R Radial R Sural R Median L Median R Ulnar Peroneal
Patient 2 SNAP (lV) 14.6 5.8 17.2 16.4 CMAP (mV) 8.7 NT 7.7 3.1
CV (m/s) 48 43 50 42 DML (ms) 4.5 NT 2.8 5.1
CV (m/s) 43 NT 44 39
F-Latency (m/s) 32.1 NT 32.9 57.1
Patient 3 SNAP (lV) 12 10.1 NT 19.4 CMAP (mV) 10.2 9.5 5.4 NT
CV (m/s) 38 40 NT 33 DML (ms) 3.6 3.7 3 NT
CV (m/s) 39 39 38 NT
F-Latency (m/s) 31 30.9 32.3 NT
Patient 5 SNAP (lV) 10.4 10.3 NT NT CMAP (mV) 5.6 1.8 2.2 NT
CV (m/s) 43 42 NT NT DML (ms) 4.9 5.4 4.2 NT
CV (m/s) 41 33 50 NT
F-Latency (m/s) NT NT NT NT
Patient 6 SNAP (lV) 16.9 18 48.7 13.4 CMAP (mV) 8.5 NT NT 3.6
CV (m/s) 37 33 42 35 DML (ms) 4.8 NT NT 4.3
CV (m/s) 38 NT NT 36
F-Latency (m/s) 35.6 NT 34.9 NT
R, right; L, left; SNAP, sensory nerve action potential; CV, conduction velocity; CMAP, compoundmotor action potential; DML, distal motor latency; F-Latency, F-wave latency;
NT, not tested.
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ularly in relation to cool-, mechanical-, and vibration-detection
threshold. There was also some evidence for gain of function, for
instance, lowered pressure pain threshold and increased wind-up
ratio in individual patients.
Skin biopsy of the lower leg was performed in Patient 5. There
was no evidence of loss of intraepidermal nerve ﬁbres. The intraep-
idermal nerve ﬁbre density was normal, at 10.67 ﬁbres/mm (rela-
tive to a mean of 10.13 ± 2.6 ﬁbres/mm in control for this
laboratory) (Fig. 3). In control subjects, as has previously been
demonstrated by Provitera et al. [23], immunostaining for both
PGP 9.5 and myelin basic protein revealed bundles of axons with
compact myelin within the dermis (Fig. 3). Despite examination
of multiple sections derived from the skin biopsy of Patient 5,
although many axons could be visualised within the dermis, none
of them were myelinated.
4. Discussion
To summarise, we report a kindred with a novel mutation in the
MPZ gene, which results in a mild form of CMT disease (in relation
to motor dysfunction and sensory loss), but debilitating neuro-
pathic pain.
MPZ is an integral membrane glycoprotein synthesised by
Schwann cells; it is the major glycoprotein of peripheral nerve
myelin and possesses an intracellular and extracellular domain.
Homotypic interactions between the extracellular domains ofMPZ mediate the compaction of myelin lamellae [6,16,18]. A large
number of different MPZ mutations have been reported in associ-
ation with CMT (Inherited Peripheral Neuropathies Mutation Data-
base: Mutations in MPZ [P0] http://www.molgen.ua.ac.be/
CMTMutations/Mutations/Mutations.cfm?Context=2). These dis-
play striking phenotypic variability and include axonal, demyelin-
ating, and intermediate forms of CMT, with differing levels of
severity from mild to severe neuropathies [29]. These can be
broadly split into 2 groups: a severe early-onset demyelinating
neuropathy and a late-onset neuropathy with predominantly axo-
nal loss. Certain mutations associated with the former have gain of
function-dominant negative effects and mutations associated with
the latter partial loss of function [9]. The Trp101X mutation is pre-
dicted to result in premature termination of translation and a trun-
cated protein lacking the transmembrane domain required for
membrane anchorage. This may, therefore, be predicted to lead
to less MPZ protein insertion into the myelin membrane. The level
of MPZ within myelin membranes was found to be normal in an-
other mutation that causes premature truncation: the heterozy-
gous Val102 frame shift mutation [30]. This indicates that there
may be potential compensatory mechanisms, although such com-
pensation for gene dosage must be incomplete, as individuals with
these mutations develop a mild neuropathy.
CMT is increasingly recognised as a cause of both nociceptive
and neuropathic pain [3,7], and there is some evidence that neuro-
pathic pain may be more common in the axonal rather than demy-
elinating forms of CMT. The distribution and nature of the pain
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Fig. 2. Quantitative sensory testing comparison of the lower limbs using z scores. (a) Patient 5. (b) Patient 2. Paradoxical heat sensations on Patient 5 were seen bilaterally (3
on each side); pain ratings did not show evidence of dynamic mechanical allodynia. CDT, cold-detection threshold; WDT, warm-detection threshold; TSL, thermal sensory
limen; CPT, cold-pain threshold; HPT, heat-pain threshold; PPT, pressure-pain threshold; MPT, mechanical-pain threshold; MPS, mechanical-pain sensitivity; WUR, wind-up
ratio; MDT, mechanical-detection threshold; VDT, vibration-detection threshold.
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ropathic in nature, and these patients would fulﬁl recent criteria
for deﬁnite neuropathic pain [32]. There have been occasional re-
ports of neuropathic pain associated with MPZ mutations. Burns
et al. reported a patient who developed an acute neuropathy with
pain as a prominent feature, evidence of demyelination on neuro-
physiology, who was found to have an Arg36Trp mutation in MPZ
[2]. Schneider-Golf et al. report a German kindred with an As-
p234Tyr missense mutation resulting in a neuropathy with fea-
tures of intermediate conduction, the predominant symptom
being burning sensations in the arms and legs as well as muscle
cramps [26]. Such reports are, however, the exception rather than
the rule.
A number of other frame shift or premature stop MPZ muta-
tions leading to a nonfunctional truncated MPZ protein in the het-
erozygous state (ie, those mutations likely to share the same
pathophysiological mechanisms as the Trp101x mutation) have
been described as causing a mild neuropathy with intermediate
conduction. The symptoms are often predominantly sensory ratherthan motor, including paraesthesia and muscle cramps; and the in-
dex case carrying the Glu71stop mutation described by Lagueny
et al. complained of burning pain of the extremities
[15,20,21,35]. It should be noted that some subjects carrying such
mutations have, however, been reported to be asymptomatic, indi-
cating potential modifying factors.
Extensive preclinical literature exists regarding the aetiology of
neuropathic pain following traumatic nerve injury or in the context
of axonal neuropathies [19]. Less is known regarding the patho-
physiology of neuropathic pain in demyelinating neuropathies. Pri-
mary demyelination has been shown to induce neuropathic pain-
related hypersensitivity that was associated with ectopic activity
in primary afferents [34]. Mice that lack the myelin constituent
periaxin have been shown to develop ectopic activity in primary
afferents and pain-related hypersensitivity [8] associated with
demyelination. The generation of neuropathic pain by demyelina-
tion may relate to a number of potential mechanisms, including
the redistribution of ion channels in demyelinated axolemma
[25], Schwann cell proliferation [1], the release of cytokines and
MBP
PGP9.5
PGP9.5 MBP
Type IV Collagen
PGP9.5
c d e
f g h
a b
Fig. 3. Immunohistochemistry. A maximum intensity projection of a confocal image of a lower-limb skin biopsy from a control subject (a) and Patient 5 (b) immunostained
for protein gene product (PGP) 9.5 (red) to demonstrate axons and collagen type 4 (green) to show the basement membrane of the epidermis. There is no difference in the
number of intraepidermal nerve ﬁbres (arrows). (c-h) Confocal images of the dermis immunostained for PGP 9.5 [(c, f) red] and myelin basic protein [(d, g) MBP, green]. In
Patient 5 (f, g, h), although numerous axons can be seen, there are no myelinated internodes, while in a control subject (c, d, e), numerous myelinated internodes were
observed. Scale Bar: 50 lm.
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as macrophages [17]. The neuropathic pain reported in relation
to the MPZ mutations described by Burns et al. and Schneider-Gold
et al. was thought to partially have an immune aetiology, given the
acute onset, and in one case, the patient’s pain responded to treat-
ment with intravenous immunoglobulin [2,26].
The majority of our patients with the Trp101X mutation had
evidence of distal, symmetrical sensory impairment on bedside
testing. Only 2 patients agreed to detailed quantitative sensory
testing, making it difﬁcult to draw deﬁnitive conclusions about
the pattern of sensory dysfunction in these patients. Both patients
had a tendency to raised detection thresholds to cooling, which is
likely to relate to impaired function in thin myelinated ﬁbres [5].
In relation to the function of largemyelinated sensory ﬁbres, one pa-
tient had raised mechanical-detection threshold in response to the
application of von Frey ﬁlaments and impaired vibration detection.
There were also some signs of hypersensitivity to sensory stimuli
applied to the foot, including a unilateral enhanced wind-up ratio
and lowered pressure pain threshold. In one patient who consented
to a skin biopsy, there was no evidence of loss of C ﬁbres within the
epidermis of the lower leg (a region that was symptomatic inrelation to pain). We had hoped to assess whether there was
evidence of demyelination and altered ion channel distribution in
myelinated dermal ﬁbres. Myelinated internodes have previously
been reported in skin biopsy samples [23] and were reliably ob-
served in our control samples. We could not, however, visualise
any myelinated internodes in the patient with the Trp101X MPZ
mutation despite immunostaining of sections throughout the
sample. This may be indicative of distal demyelination; however,
we cannot exclude the possibility that this could be a sampling
issue. It is likely that dysfunction in sensory axons that would
normally be myelinated is responsible for the neuropathic pain in
these patients.
These cases emphasise the heterogeneity of the phenotype of
MPZ mutations, the fact that mutations in myelin proteins can re-
sult in disabling neuropathic pain and that there is no simple rela-
tionship between overall neuropathy severity and the degree of
neuropathic pain.
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